Role of MRD Negativity Rates in Treatment Decision Making

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.

This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.